Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ebola virus vaccine - Hawaii Biotech/Soligenix/University of Hawaii

Drug Profile

Ebola virus vaccine - Hawaii Biotech/Soligenix/University of Hawaii

Alternative Names: Ebola subunit vaccine - Soligenix; SuVax™

Latest Information Update: 02 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hawaii Biotech; Soligenix; University of Hawaii
  • Developer Soligenix; University of Hawaii
  • Class Subunit vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ebola virus infections
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Ebola virus infections

Most Recent Events

  • 25 Apr 2024 Soligenix receives notice of intent to grant additional patents based on its patent compositions and methods of manufacturing trivalent filovirus vaccines in the United Kingdom and South Africa, with other international jurisdictions pending
  • 11 Apr 2024 Ebola virus vaccine receives Orphan Drug status for Ebola virus infections (Prevention) in USA
  • 08 Nov 2022 Soligenix receives patent allowance for compositions and methods of manufacturing of Trivalent filovirus vaccines in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top